HC Wainwright Forecasts Weaker Earnings for Nuvation Bio

Nuvation Bio Inc. (NYSE:NUVB) – Equities research analysts at HC Wainwright dropped their Q1 2026 earnings per share estimates for Nuvation Bio in a research note issued on Tuesday, March 3rd. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.13) per share for the quarter, down from their prior forecast of ($0.11). HC Wainwright currently has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.44) EPS.

Nuvation Bio (NYSE:NUVB) last posted its earnings results on Monday, March 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). The business had revenue of $41.87 million during the quarter, compared to analyst estimates of $36.82 million. Nuvation Bio had a negative return on equity of 57.48% and a negative net margin of 325.31%.

Several other brokerages also recently weighed in on NUVB. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvation Bio in a research note on Thursday, January 22nd. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Nuvation Bio in a report on Tuesday, February 10th. B. Riley Financial assumed coverage on shares of Nuvation Bio in a research report on Wednesday, November 19th. They issued a “buy” rating and a $12.00 price objective for the company. Truist Financial set a $13.00 target price on Nuvation Bio in a research report on Tuesday, January 27th. Finally, UBS Group cut their price target on Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating on the stock in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $11.44.

Nuvation Bio Stock Up 8.7%

Shares of NYSE:NUVB opened at $4.74 on Thursday. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of -7.90 and a beta of 1.50. The company has a 50 day moving average of $6.45 and a two-hundred day moving average of $5.53. Nuvation Bio has a 52-week low of $1.54 and a 52-week high of $9.75. The company has a quick ratio of 8.39, a current ratio of 6.95 and a debt-to-equity ratio of 0.15.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Nuvation Bio by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 15,555,606 shares of the company’s stock valued at $139,378,000 after acquiring an additional 101,011 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Nuvation Bio by 16.8% in the second quarter. Geode Capital Management LLC now owns 5,994,798 shares of the company’s stock worth $11,691,000 after purchasing an additional 864,194 shares during the period. Millennium Management LLC boosted its holdings in Nuvation Bio by 52.4% in the first quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock worth $6,642,000 after purchasing an additional 1,298,131 shares during the period. Dimensional Fund Advisors LP increased its stake in Nuvation Bio by 19.9% during the third quarter. Dimensional Fund Advisors LP now owns 3,321,249 shares of the company’s stock valued at $12,276,000 after purchasing an additional 551,508 shares during the last quarter. Finally, Aisling Capital Management LP raised its holdings in shares of Nuvation Bio by 16.5% during the third quarter. Aisling Capital Management LP now owns 2,960,659 shares of the company’s stock worth $10,954,000 after purchasing an additional 419,650 shares during the period. Institutional investors and hedge funds own 61.67% of the company’s stock.

Nuvation Bio News Summary

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: Royal Bank of Canada raised its price target to $13 and kept an Outperform stance, providing a near-term bullish analyst endorsement that supports upside expectations. RBC Boosts NUVB Price Target
• Positive Sentiment: Nuvation announced it is transitioning to the commercial stage with progress on Iptrozi and safusidenib, a fundamental milestone that can lift revenue visibility and long-term valuation if launches and uptake go as planned. Nuvation Transitions To Commercial Stage
• Neutral Sentiment: H.C. Wainwright reiterated a Buy rating and a $17 price objective, signaling continued long‑term confidence from that shop despite other adjustments. H.C. Wainwright Sticks to Buy
• Negative Sentiment: H.C. Wainwright sharply lowered its EPS forecasts for Q1–Q4 and cut FY2026 to ($0.44) from ($0.35), signaling weaker near‑term profitability expectations that can pressure the stock despite the maintained Buy rating. HC Wainwright EPS Cuts
• Negative Sentiment: UBS trimmed its price target (from $10 to $7) and flagged lower expectations, reducing a key source of analyst support and likely weighing on sentiment. UBS Lowers Expectations
• Negative Sentiment: Johnson Fistel has opened an investor investigation into potential securities-law claims against Nuvation and its officers, introducing legal/settlement risk and additional uncertainty for investors. Johnson Fistel Investigation
• Negative Sentiment: Analyst commentary (TipRanks) highlights new commercialization and partner‑execution risks for taletrectinib, underscoring operational challenges that could hinder product rollouts and revenue. Taletrectinib Commercialization Risk

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.